MilliporeSigma Announces Siren Biotechnology As Winner Of Its North American Advance Biotech Grant

• Siren Biotechnology to receive products, technologies and contract testing services to develop gene therapy treatments for cancer
• Experts from MilliporeSigma‘s Emprove^® team and M Lab™ Collaboration Center to provide consultation and training
• Company has awarded grants to 40-plus biotechnology companies since 2014

Burlington, MA – MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced today that Siren Biotechnology has been selected as the North American winner of its 13th Advance Biotech Grant Program. The biotechnology startup, which is headquartered in San Francisco, California, USA, was selected for the development of its universal adeno-associated virus (AAV) immuno-gene therapy for cancer.

"Emerging biotech companies play a critical role in driving innovation and development in life sciences, owning 60 percent of the current drug pipeline¹ ,” said Sebastian Arana, Head of Process Solutions, Life Science business of Merck KGaA, Darmstadt, Germany. “Our Advance Biotech Grant Program provides the products, technologies and services to help these companies bring their life-changing innovations to market, and ultimately, patients around the world.”

Millions of people worldwide are affected by cancer. To meet the demand for cancer-treating therapies, Siren Biotechnology is developing a universal AAV immuno-gene therapy platform designed to reduce development and manufacturing timelines, while also working for numerous types of cancer.

As part of the award, Siren Biotechnology will receive a wide range of support from MilliporeSigma, including Millipore^® bioprocessing products, technologies and consultative services, and close partnership with the company to screen different media formulations to help optimize AAV yield. Siren Biotechnology will leverage the company's BioReliance^® Contract Testing Services for AAV testing, as well as consultation services and training by technical experts from the Emprove^® team and M Lab™ Collaboration Center. Managed by an experienced team of engineers and scientists, MilliporeSigma’s M Lab™ Collaboration Centers allow customers to explore technical solutions, test applications, assess technologies, and optimize processes. Additionally, MilliporeSigma’s Emprove^® Program combines high-quality products, comprehensive documentation, and customer support to facilitate qualification, risk assessment, and process optimization.

Since 2014, the Life Science business’s Advance Biotech Grant Program has awarded technologies and consultation to more than 40 biotechnology companies around the world, supporting their efforts to improve patient outcomes for various diseases such as cancer, brain tumors, osteoarthritis, and cardiovascular disorders. The company is set to award additional grants in APAC in July and EMEA in November, further expanding its commitment to supporting emerging biotech companies worldwide.

¹ Q24 Molecule Pipeline from Evaluate Pharma, Global Data and CNDA

About the Life Science business of Merck KGaA, Darmstadt, Germany

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 28,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.

Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck KGaA, Darmstadt, Germany, generated sales of € 21 billion in 65 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.